Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) CEO John Treace bought 49,013 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $2.46 per share, with a total value of $120,571.98. Following the purchase, the chief executive officer owned 7,096,563 shares in the company, valued at $17,457,544.98. The trade was a 0.70% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Treace Medical Concepts Stock Performance
NASDAQ TMCI opened at $2.66 on Friday. The firm has a 50-day moving average of $1.69 and a 200-day moving average of $2.49. The company has a debt-to-equity ratio of 0.72, a quick ratio of 3.13 and a current ratio of 3.58. The stock has a market cap of $172.55 million, a PE ratio of -2.74 and a beta of 1.10. Treace Medical Concepts, Inc. has a 52-week low of $1.17 and a 52-week high of $7.78.
Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. The company had revenue of $47.20 million during the quarter, compared to analysts’ expectations of $45.96 million. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. On average, sell-side analysts anticipate that Treace Medical Concepts, Inc. will post -0.88 EPS for the current year.
Hedge Funds Weigh In On Treace Medical Concepts
Analysts Set New Price Targets
A number of research firms have recently issued reports on TMCI. Wall Street Zen upgraded shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Monday, April 20th. Finally, Lake Street Capital cut their target price on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Treace Medical Concepts presently has a consensus rating of “Reduce” and an average target price of $4.77.
Check Out Our Latest Stock Analysis on Treace Medical Concepts
Treace Medical Concepts Company Profile
Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.
The Lapiplasty System has received clearance from the U.S.
Featured Stories
- Five stocks we like better than Treace Medical Concepts
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.
